dc.contributor.author | Gutiérrez-Fernández, María | |
dc.contributor.author | Otero-Ortega, Laura | |
dc.contributor.author | Ramos-Cejudo, Jaime | |
dc.contributor.author | Rodríguez-Frutos, Berta | |
dc.contributor.author | Fuentes Gimeno, Blanca Eulalia | |
dc.contributor.author | Díez Tejedor, Exuperio | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | es_ES |
dc.date.accessioned | 2016-05-30T14:20:34Z | |
dc.date.available | 2016-05-30T14:20:34Z | |
dc.date.issued | 2015-06-01 | |
dc.identifier.citation | Expert Opinion on Biological Therapy 15.6 (2015): 873-81 | es_ES |
dc.identifier.issn | 1471-2598 | es_ES |
dc.identifier.issn | 1744-7682 (on line) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/671137 | |
dc.description.abstract | Introduction: Based on the positive results observed in experimental animal models, adipose
tissue-derived mesenchymal stem cells (AD-MSCs) constitute a promising therapy for stroke
treatment. However, several aspects need to be clarified to identify the optimal conditions for
successful clinical translation.
Areas covered: This review focuses on AD-MSC treatment for ischemic and hemorrhagic stroke
in experimental animal models. In addition, we will explore the optimization of treatment
conditions including AD-MSC production, administration routes and therapeutic windows for
their appropriate use in patients, and we will provide an update on clinical trials on this
therapy.
Expert opinion: Compared with other cell types, AD-MSCs have been less investigated in
stroke studies. Currently, experimental animal models have shown safety and efficacy with this
treatment after stroke. Due to several advantages of AD-MSCs, such as their abundance and
accessibility, they can be considered a promising strategy for use in patients. However, many
questions are still to be resolved regarding their mechanisms of action, immune system
modulation and the effects of AD-MSCs on all components of the brain that may be affected
after ischemic and hemorrhagic strokes | es_ES |
dc.description.sponsorship | This project is supported by research grants PS12/01754 (Spanish Ministry of Science) and
INVICTUS (RD12/0014/0006) (Spanish Neurovascular Network), and Research Institute Carlos
III, Ministry Science and Innovation | es_ES |
dc.format.extent | 21 pag. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Informa Healthcare | es_ES |
dc.relation.ispartof | Expert Opinion on Biological Therapy | es_ES |
dc.subject.other | Adipose tissue | es_ES |
dc.subject.other | Hemorrhagic stroke | es_ES |
dc.subject.other | Ischemic stroke | es_ES |
dc.subject.other | Mesenchymal stem cells | es_ES |
dc.title | Adipose tissue-derived mesenchymal stem cells as a strategy to improve recovery after stroke | es_ES |
dc.type | article | es_ES |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1517/14712598.2015.1040386 | es_ES |
dc.identifier.doi | 10.1517/14712598.2015.1040386 | es_ES |
dc.identifier.publicationfirstpage | 873 | es_ES |
dc.identifier.publicationissue | 6 | es_ES |
dc.identifier.publicationlastpage | 881 | es_ES |
dc.identifier.publicationvolume | 15 | es_ES |
dc.relation.projectID | Gobierno de España. PS12/01754 | es_ES |
dc.type.version | info:eu-repo/semantics/draft | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.authorUAM | Díez Tejedor, Exuperio (258291) | |
dc.authorUAM | Fuentes Gimeno, Blanca Eulalia (262687) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | |